Genzyme Recognized by Scientists as a Top Employer

Genzyme CorporationGenzyme Corporation (Nasdaq: GENZ) has announced that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. This year Genzyme moved up in the ranking to third on the global list of nearly 500 companies, the highest ranking it has ever earned. Out of companies headquartered in New England Genzyme topped the list. This is the sixth year that Genzyme has placed among the top 10 of all biotechnology and pharmaceutical companies.

The survey, which was commissioned by Science magazine and the American Association for the Advancement of Science (AAAS), identified the top 20 companies with the best reputations as employers. More than 4,000 Science readers and other industry representatives participated in the survey. Genzyme earned the most votes in the following categories: innovative leader in the industry, a socially responsible company and having loyal employees.

"Our scientists are united by a common goal: to improve the lives of people who have serious diseases," said Alan Smith, Ph.D., senior vice president of research and chief scientific officer at Genzyme. "Because of their dedication and talent Genzyme will continue to develop breakthrough therapies."

About the Survey
Science and AAAS commissioned a web-based survey to determine the biotechnology and pharmaceutical companies with the best reputations as employers. For this year's survey, a mixed methodology was used. The first part of this methodology included e-mailed invitations to AAAS members, ScienceCareers.org registrants, and Science website visitors registered with AAAS. The second part of the methodology included an e-mail blast to more than 600 human resource contacts from the ScienceCareers.org database.

Survey respondents were asked to write in the names of companies they considered best, average and worst employers. They then rated these companies on 23 different attributes. Attribute categories included Corporate Image, Leadership and Direction, Financial Prowess, Work Culture/Environment, Work/Life Balance, Academics and Collegial Exchange, and Compensation and Benefits. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and more than 90 percent worked in private industry.

"We believe that promoting an environment that encourages employees to take risks and is socially responsible helps to foster employee loyalty and attract new talent," said Zoltan Csimma, senior vice president and chief human resources officer at Genzyme. "We are honored to be recognized as one of the top three companies in the world for scientists."

Genzyme is a leader in the effort to develop and apply the most advanced scientific technologies. Scientists working at Genzyme have developed novel treatments that are helping patients in more than 90 countries worldwide. The company is bringing new and next-generation therapies to patients with genetic diseases, kidney disease, cancer, osteoarthritis, as well as transplant and immune diseases. The company is also a leader in the development of diagnostic and genetic tests.

The survey results will appear in a special business supplement of the 10 October 2008 issue of Science.

For information about careers at Genzyme, please visit: http://www.genzyme.com/careers

About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...